Fluoromedroxyprogesterone acetate (FMPA, 9α-fluoromedroxyprogesterone acetate, or 9α-FMPA) is a synthetic steroid medication which was under development by Meiji Dairies Corporation in the 1990s and 2000s for the potential treatment of cancers but was never marketed.

[1][2][3][4][5][6][7] It is described as an antiangiogenic agent, with about two orders of magnitude greater potency for inhibition of angiogenesis than its parent compound medroxyprogesterone acetate.

[2][4][5] FMPA showed about the same affinities for the progesterone and glucocorticoid receptors as MPA.

[4] It reached the preclinical phase of research prior to the discontinuation of its development.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.